Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132379 · ClinicalTrials.gov registry record · Phase 1
ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer
A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Active Biotech AB.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 4
- Study locations
NCT00132379: Completed Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Active Biotech AB.
NCT00132379 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that has completed, run by Active Biotech AB. The registered enrollment target is 13 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00132379, a Phase 1 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Active Biotech AB.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 4
- Study locations
Study Summary
The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. In animals, this results in an accumulation of white blood cells in the cancer that can fight the cancer. This study will test how much of the drug, in combination with docetaxel (an approved drug for treating non-small cell lung cancer \[NSCLC\]), can be given to patients with NSCLC without causing unacceptable side effects.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG ABR-217620
Study Locations (4)
Other
- Onkologisk Klinik, Rigshospitalet - Copenhagen
- City Multifield Hospital #2, City Center of Intensive Pulmonology and Thoracic Surgery - Saint Petersburg
- St. Petersburg Pavlov State Medical University - Saint Petersburg
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
What the finished NCT00132379 record still lists
NCT00132379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.
NCT00132379 reports a single indexed study location in Other, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00132379 about?
NCT00132379 is a clinical study titled "ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer". The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. In animals, this results in an accumulation of white blood cells in the cancer t...
What is the current status of trial NCT00132379?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2005-11. Estimated completion is 2006-12.
What conditions does trial NCT00132379 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT00132379?
The interventions under investigation include: docetaxel (DRUG), ABR-217620 (DRUG).
Who is sponsoring clinical trial NCT00132379?
This trial is sponsored by Active Biotech AB, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00132379 being conducted?
This trial has 4 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00132379's enrollment target sits among peer trials
13 126th of 130 higher than 5 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia